Skip to main content
Premium Trial:

Request an Annual Quote

AstraZeneca Signs on as First Partner for BioWisdom's Toxicity Safety Program

NEW YORK (GenomeWeb News) - AstraZeneca has signed a three-year agreement for BioWisdom’s Safety Intelligence Program, an initiative to develop an “intelligence system” to analyze drug safety and toxicity data for use in drug discovery and development.
 
BioWisdom said AstraZeneca is its first partner for the program, and as such takes a place on the firm’s SIP advisory board. 
 
The SIP program will support development of methods for identifying and analyzing toxicities, characterizing mechanisms of protein targets with toxic effects, predicting and evaluating potential toxicity issues, comparing species for animal models, and planning and designing clinical trials, BioWisdom said.

Filed under

The Scan

mRNA-Based Vaccine on the Way in China

China may soon have its own mRNA-based vaccine, according to Nature News.

Arranged Killing, Fraud Alleged by Prosecutors

The Wall Street Journal reports that prosecutors allege that the co-founder of a biotech arranged to have a business associate who threatened to expose him as a fraud killed.

Whirlwind Decade of CRISPR

The New York Times looks back at the 10 years since the University of California, Berkeley's Jennifer Doudna and her colleagues published their CRISPR paper.

PNAS Papers on Blue Cone Monochromacy Structural Variants, HIV-1 Mutant, T-ALL

In PNAS this week: structural variants linked to blue cone monochromacy, HIV-1 variants affecting the matrix protein p17, and more.